I would differ on that opinion of the audiologist not wanting to support it, don't think that was the issue, look at Audeara, they manage it perfectly. It is how you go about securing the audiologist sales channels that makes or breaks it. On the big box, when you call it a hearing aid, it has no new customers, as customers dont go to big box for a hearing aid as they don't know they have a hearing problem. If they do know they have a hearing problem, then you are only getting the leftover sales from people with small budgets who could not get the hearing aid at the right price from the audiologist. Then when they go shopping, in big box for a deal, they are not going to buy Nuheara at 699 USD, as you have said before, its way too expensive, , hence the almost flatline sales. Totally agree with you on the oversized buds, that was a problem from the outset, and the change in design should have come about in the Max, it is now way too late for changing anything.
What they needed at the helm was a large audiology CEO from a retailer, who knows how to sell the devices and where to. I do hope they find an exit strategy, but you really cannot see where that exit will come from now.
- Forums
- ASX - By Stock
- Ann: March 2024 Quarterly Appendix 4C
I would differ on that opinion of the audiologist not wanting to...
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUH (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NUH (ASX) Chart |
Day chart unavailable